Celecoxib vs Meloxicam

Both celecoxib and meloxicam are effective for osteoarthritis and rheumatoid arthritis. Celecoxib 200 mg daily is comparable to ibuprofen 800 mg three times daily and naproxen 500 mg twice daily for arthritis pain relief ^[1]. Meloxicam 15 mg daily provides similar analgesic efficacy to piroxicam 20 mg daily and diclofenac 100 mg daily ^[2]. Head-to-head comparisons are limited, but available data suggest comparable pain relief and functional improvement ^[3]. Celecoxib has FDA approval for osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea ^[1]. Meloxicam is approved for osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis ^[2]. For acute pain conditions, celecoxib has broader evidence and indications. Both reduce morning stiffness and improve joint function in chronic arthritis with sustained use ^[4].

The most important distinction is gastrointestinal safety. Celecoxib's selective COX-2 inhibition spares the gastroprotective COX-1–derived prostaglandins, resulting in significantly fewer GI ulcers (2–4% vs 6–12% with traditional NSAIDs over 6 months) ^[1]. The CLASS trial demonstrated celecoxib's GI advantage over ibuprofen and diclofenac ^[3]. Meloxicam's preferential COX-2 selectivity provides some GI protection compared to non-selective NSAIDs, but less than celecoxib — ulcer rates are approximately 4–7% ^[2]. The cardiovascular question was definitively addressed by the PRECISION trial (>24,000 arthritis patients), which found celecoxib non-inferior to ibuprofen and naproxen for cardiovascular thrombotic events, effectively reassuring clinicians about celecoxib's cardiac safety at moderate doses (200 mg/day) ^[3]. Meloxicam's cardiovascular safety has less definitive trial data but appears comparable to other NSAIDs. Both carry the standard FDA boxed warning for cardiovascular and GI risks ^[4]. Both can affect renal function, raise blood pressure, and cause fluid retention. Celecoxib is contraindicated in patients with sulfonamide allergy ^[1].

This is where a significant difference exists. Generic celecoxib 200 mg (30 capsules) costs $15–40, which is substantially more than most generic NSAIDs ^[1]. Generic meloxicam 15 mg (30 tablets) costs $4–10, often on pharmacy $4 generic lists ^[2]. Brand-name Celebrex costs $300–500/month, while brand Mobic costs $100–200/month. For cost-sensitive patients, meloxicam offers a substantial advantage. However, if celecoxib is prescribed specifically for GI protection, comparing its cost to meloxicam plus a PPI (which adds $8–20/month) may close the gap ^[3]. Both are covered by most insurance plans, though celecoxib may require a higher copay tier or prior authorization on some formularies.

Both offer convenient once-daily dosing for arthritis. Celecoxib is taken at 100–200 mg once or twice daily (maximum 400 mg/day), and can be taken with or without food ^[1]. Meloxicam is taken at 7.5–15 mg once daily, also with or without food ^[2]. Celecoxib capsules come in 50, 100, 200, and 400 mg strengths. Meloxicam is available in 7.5 and 15 mg tablets and an oral suspension. Neither requires routine laboratory monitoring beyond periodic renal function and blood pressure checks recommended for all chronic NSAID users ^[3]. Celecoxib capsules can be opened and sprinkled on applesauce for patients with swallowing difficulty. Both drugs reach steady-state within 3–5 days of regular dosing ^[4].

Celecoxib may be preferred for patients at higher GI risk (history of ulcers, age >65, concurrent anticoagulant use) who need an NSAID and want to avoid adding a PPI, patients with sulfa allergy should not use it however ^[1][3]. It is also preferred for acute pain indications (broader FDA approval) and patients reassured by the PRECISION trial's cardiovascular safety data. Meloxicam may be preferred when cost is a significant factor (3–4 times cheaper), for patients with mild GI risk where its preferential COX-2 selectivity provides adequate protection, and for patients who prefer a medication on the $4 generic list ^[2]. For patients with high cardiovascular risk, naproxen remains the preferred NSAID per AHA guidance, regardless of GI considerations ^[4]. Both drugs should be used at the lowest effective dose for the shortest duration. Consult your healthcare provider to weigh GI protection against cost for your individual situation.